A 48-year-old woman with hepatitis C-related cirrhosis is evaluated for complications. She has ascites, jaundice, and coagulopathy. Regarding the complications and metabolic derangements in advanced cirrhosis, all of the following contribute to hepatic encephalopathy EXCEPT:

Explanation

## Pathogenesis of Hepatic Encephalopathy in Cirrhosis **Key Point:** Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome caused by multiple metabolic derangements, primarily ammonia accumulation, altered amino acid metabolism, and increased inhibitory neurotransmitters. Hyperkalemia is NOT a primary mechanism. ### Mechanisms of Hepatic Encephalopathy | Mechanism | Pathophysiology | Evidence | |-----------|-----------------|----------| | **Ammonia accumulation** | Impaired hepatic ureagenesis + portosystemic shunting → ↑ blood NH₃ | Primary driver; correlates with HE severity | | **Altered amino acid ratio** | ↑ Aromatic AA (AAA) vs ↓ Branched-chain AA (BCAA); Fischer ratio <3 | AAA compete with BCAA for BBB transport; AAA are precursors of false neurotransmitters | | **Increased inhibitory neurotransmitters** | ↑ GABA, endogenous benzodiazepines, manganese | Enhance GABAergic inhibition in CNS | | **Neuroinflammation** | ↑ IL-6, TNF-α, oxidative stress | Contributes to astrocyte swelling and cerebral edema | | **Hyperkalemia** | NOT a primary mechanism in HE | Cirrhotic patients typically have hypokalemia, not hyperkalemia | **High-Yield:** The question tests whether students confuse the metabolic derangements in cirrhosis. While hyperkalemia does occur in acute liver failure, cirrhotic patients typically have **hypokalemia** due to increased renal potassium wasting (secondary hyperaldosteronism) and poor oral intake. Hyperkalemia is NOT a mechanism of HE. ### The Ammonia Hypothesis 1. **Impaired ureagenesis:** Cirrhotic liver cannot convert ammonia to urea efficiently 2. **Portosystemic shunting:** Blood bypasses hepatic detoxification via collateral vessels 3. **Result:** Ammonia crosses the blood-brain barrier and is metabolized by astrocytes to glutamine, causing osmotic stress and cerebral edema **Clinical Pearl:** Lactulose and rifaxomicin reduce ammonia by: (1) acidifying colonic pH (lactulose), reducing ammonia absorption, and (2) reducing ammonia-producing bacteria (rifaxomicin). ### Fischer Ratio and Amino Acid Imbalance **Mnemonic: BCAA vs AAA in HE** - **BCAA** (Branched-Chain Amino Acids): Leucine, Isoleucine, Valine — ↓ in HE - **AAA** (Aromatic Amino Acids): Phenylalanine, Tyrosine, Tryptophan — ↑ in HE - **Fischer ratio** = (Leucine + Isoleucine + Valine) / (Phenylalanine + Tyrosine) - Normal: 3–4; HE: <1.5 - AAA are precursors of false neurotransmitters (octopamine, phenylethylamine) that impair normal synaptic transmission ### Why Hyperkalemia is NOT a Mechanism Circrhotic patients typically develop **hypokalemia**, not hyperkalemia, due to: - Secondary hyperaldosteronism → renal potassium wasting - Poor oral intake - Diuretic use for ascites management - Diarrhea from lactulose therapy Hyperkalemia occurs in acute liver failure (ALF) with renal failure, not in chronic cirrhosis with HE. [cite:Harrison 21e Ch 297] ## Treatment Approach for Hepatic Encephalopathy ```mermaid flowchart TD A[Hepatic Encephalopathy]:::outcome --> B{Identify precipitant}:::decision B -->|Infection| C[Antibiotics]:::action B -->|Renal failure| D[Dialysis/CRRT]:::action B -->|GI bleed| E[Variceal management]:::action B -->|Medication| F[Review drugs]:::action A --> G[Reduce ammonia]:::action G --> G1[Lactulose/Lactitol]:::action G --> G2[Rifaxomicin]:::action G --> G3[BCAA supplementation]:::action A --> H[Correct metabolic derangements]:::action H --> H1[Hypokalemia correction]:::action H --> H2[Hypoglycemia correction]:::action H --> H3[Acid-base balance]:::action ```